Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2010
06/29/2010US7744903 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination; host cells
06/29/2010US7744902 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
06/29/2010US7744901 A reassortant influenza virus comprises 6 internal genome segments from A/Ann Arbor/6/60 and one genome segment comprising a nucleic acid encoding a hemagglutinin polypeptide comprising the amino acid sequence of SEQ ID NO: 11; live, split or killed vaccine; immunostimulants
06/29/2010US7744900 Expression cassettes provided comprising a promoter operably linked to a nucleic acid which when transcribed in vivo, forms double stranded RNA that induces the production of interferon(alpha, beta, or gamma) either directly or indirectly, which in turnmay upregulate MHC Class I and/ or II
06/29/2010US7744898 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
06/29/2010US7744897 Human immunodeficiency virus gp41 mimetibody polypeptides
06/29/2010US7744896 therapeutic vaccine anti-HIV, anti-AIDS and against tumors and syndromes associated with HIV infection
06/29/2010US7744895 treating a food allergy; orally administer 100 mu g/kg or more of transforming growth factor-beta (TGF- beta ); no side effects
06/29/2010US7744894 Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24
06/29/2010US7744893 autoimmune disease; treating and monitoring multiple sclerosis by utilizing T-cell receptors peptides; vaccine
06/29/2010US7744892 Optimized expression of HPV 52 L1 in yeast
06/29/2010US7744891 Using lymphotoxin-beta receptors ligand specific immunoglobulin as therapeutic agent in treatment and prevention of lupus and thrombocytopenia
06/29/2010US7744890 reducing the concentration of salts such as sodium chloride, in an antibody preparation to reduce the opalescent appearance of the preparation and/or the formation of high molecular weight proteins in the preparation
06/29/2010US7744889 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents
06/29/2010US7744888 Controlling immunology response; autoimmune disease, antiallergens
06/29/2010US7744887 Human scFvs which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV; reducing viral load levels within an infected individual
06/29/2010US7744886 Methods for interfering with rank signaling
06/29/2010US7744885 administering antibodies or antigen-binding fragments which are specific for human tumor necrosis factor- alpha (TNF alpha), used for in vivo medical diagnosis and therapy; immunoassay and immunotherapy
06/29/2010US7744884 Using toll-like receptor 4 specific immunoglobulin as therapeutic tool in treatment and prevention of inflammatory bowel, atherosclerotic and arthritic disorders
06/29/2010US7744882 Human estrogen specific immunoglobulin for use as evaluative tool in diagnosing/prognosing metastatic cancers; evaluating efficacy of anticancer treatment
06/29/2010US7744881 for cancer treatment by inducing apoptosis; monoclonal antibodies; drug conjugated with polyoxyethylene glycol or enzyme or radioisotope, fluorescent compound or chemiluminescent compound; genetic engineering; biodrugs; anticarcinogenic agents
06/29/2010US7744880 cell proliferation-inhibiting activity by ADCC (antibody-dependent cell-mediated cytotoxicity) activity and CDC (complement-dependent cytotoxicity); hepatic cancer
06/29/2010US7744879 Blood-brain barrier targeting antibodies
06/29/2010US7744878 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
06/29/2010US7744877 Administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies for treating B cell lymphoma
06/29/2010US7744876 A soluble immunoglobulin-polypeptide chimera comprising an immunoglobulin having a complementarity determining region 3 (CDR3); endocytic presentation of an immunosuppressive factor for the down regulation of diabetogenic T cells for the treatment of type 1 diabetes
06/29/2010US7744875 Administering antibodies, CD antigens in a dosage sufficient to induce a breakthrough event that can be detectable such as diarrhea, enterocolitis, dermatitis, hypophysitis, panhypopituitarism, rash, pruritis, dermatitis, vitiligo, and enterocolitis; for cancer treatment
06/29/2010US7744874 Anti-sclerostin antibodies
06/29/2010US7744873 Extracting DNA from a blood or buccal cell sample, PCR, resolution, and identification of differences in sequences between the extracted DNA and PCR primers; drug screening
06/29/2010US7744872 Which bind specifically to polypeptides; for microtiter plate and enzyme linked immunosorbent assay; diagnosis and treatment of canine and human ehrlichiosis; sensitivity and specificity
06/29/2010US7744871 comprising an antibody against an EGF receptor and a vaccine which induces antibodies against EGF or TGF alpha; based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK)
06/29/2010US7744870 A conjugated compound contains antibody or a Fab, and a radiostable therapeutic active agent; for diagnosis/therapy of colorectal cancer; biological conjugated drugs
06/29/2010US7744866 IL-1β binding antibodies and binding fragments thereof
06/29/2010US7744865 comprising heavy chain and light chain variable regions that binds to human interleukin-1 beta with a dissociation constant less than 1 pM; time-release and sustained-release drugs
06/29/2010US7744863 inhibiting Th1 immune response of an anti-CD3 monoclonal antibody and IL-5; type I diabetes, multiple sclerosis, rheumatoid arthritis, psoriasis, glomerulonephritis, myasthenia gravis, chronic inflammatory demyelinating neuropathy and inflammatory bowel disease; autoimmune disease
06/29/2010CA2482747C Vaccine composition for preventing meningococcal disease
06/29/2010CA2417923C Vaccination against host cell-associated herpesviruses
06/29/2010CA2401942C Pharmaceutical compositions for buccal and pulmonary application
06/29/2010CA2390082C Novel hcv non-structural polypeptide
06/29/2010CA2370477C Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
06/29/2010CA2337969C Compound and method for the prevention and/or the treatment of allergy
06/29/2010CA2325345C Medicaments for inducing cytotoxic t-cells
06/29/2010CA2252372C Pathogenic escherichia coli associated protein
06/29/2010CA2236700C Immunity against pasteurella haemolytica leukotoxin
06/29/2010CA2225470C Method and apparatus for inactivating contaminants in blood products
06/29/2010CA2163976C Methods and compositions for inhibiting cd14 mediated cell activation
06/24/2010WO2010071880A1 Tnfr25 agonists to enhance immune responses to vaccines
06/24/2010WO2010071767A2 Na/k-atpase-derived peptide src inhibitors and ouabain antagonists and uses thereof
06/24/2010WO2010071237A1 Method for producing comprehensive anti-surface antibody wherein the antigen used is a microorganism fixed by a protein crosslinking and fixation reagent
06/24/2010WO2010071230A1 Photodynamic therapeutic agent showing accumulation of cell-specific functions
06/24/2010WO2010070877A1 Elovl7 epitope peptides and vaccines containing the same
06/24/2010WO2010070453A2 Meningococcal vaccines including hemoglobin receptor
06/24/2010WO2010070380A2 Doc1 compositions and methods for treating cancer
06/24/2010WO2010070379A1 Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
06/24/2010WO2010070145A2 Method for generation of immunoglobulin sequences
06/24/2010WO2010070134A1 Monoclonal antibodies directed against lg4-5 domain of alpha3 chain of human laminin-5
06/24/2010WO2010070117A1 Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
06/24/2010WO2010070098A1 High growth reassortant influenza a virus
06/24/2010WO2010070094A1 Myostatin binding proteins
06/24/2010WO2010069929A1 Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
06/24/2010WO2010069858A1 Pharmaceutical composition
06/24/2010WO2010069765A1 ANTI-cMET ANTIBODY
06/24/2010WO2010069532A1 Antibodies against human angiopoietin 2
06/24/2010WO2010069331A2 Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
06/24/2010WO2010069073A1 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
06/24/2010WO2010068969A1 Pcv 2-based methods and compositions for the treatment of pigs
06/24/2010WO2010068968A1 Methods and compositions for use of a coccidiosis vaccine
06/24/2010WO2010046592A3 Use of isolated polypeptides having antigenic properties against mycoplasma pneumoniae, and of corresponding polynucleotides and antibodies
06/24/2010WO2010032138A3 Vaccine adjuvant combinations
06/24/2010WO2010032059A3 Antibodies directed to cd105 and uses thereof
06/24/2010WO2010030840A3 Novel receptor and uses thereof
06/24/2010WO2010023482A3 Therapeutic antibody
06/24/2010WO2010016912A3 Immunotherapeutic compositions for the treatment of alzheimer's disease
06/24/2010WO2009158618A4 Avian reoviridae
06/24/2010WO2009089401A3 Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
06/24/2010WO2008123999A3 Anti-ige antibodies
06/24/2010US20100162421 Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
06/24/2010US20100162419 Tumor-initiating cells and methods of use
06/24/2010US20100160894 Automatic injection device
06/24/2010US20100160418 Compositions and Methods for Vaccinating Against HSV-2
06/24/2010US20100159453 Genes involved in intestinal inflammatory diseases and use thereof
06/24/2010US20100159439 Method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/24/2010US20100159004 Methods and compositions for reduction of side effects of therapeutic treatments
06/24/2010US20100158994 Nanoparticles for Delivery of Therapeutic Agents Using Ultrasound and Associated Methods
06/24/2010US20100158981 Block Biodegradable Copolymers for Medical Devices
06/24/2010US20100158955 Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity
06/24/2010US20100158954 Brucella Melitensis Mutants and Methods
06/24/2010US20100158953 Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
06/24/2010US20100158952 Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates
06/24/2010US20100158951 Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition
06/24/2010US20100158950 Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
06/24/2010US20100158949 Compositions and Methods for Vaccinating Against HSV-2
06/24/2010US20100158947 Permissive cells and uses thereof
06/24/2010US20100158946 Secretory IgA and IgG Antibody Inducer
06/24/2010US20100158945 Attenuated polio viruses
06/24/2010US20100158944 Method for influenza virus protection
06/24/2010US20100158943 Administration routes for priming/boosting with influenza vaccines
06/24/2010US20100158942 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
06/24/2010US20100158941 Compositions and Methods for Treating Microbial Infections
06/24/2010US20100158940 Manufacture of booster vaccines having reduced antigen doses
1 ... 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 ... 1823